Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 4248
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 9  |  Issue : 8  |  Page : 3933-3936

Effect of Glucagon-like peptide-1 agonist (liriglutide) on weight and glycemic control among adults with type 2 diabetes mellitus attending primary care center at security forces hospital in Riyadh, Saudi Arabia


Department of Family Medicine, Security Forces Hospital, Riyadh, Saudi Arabia

Correspondence Address:
Dr. Naifah K Alanazi
Department of Family Medicine, Security Forces Hospital, Riyadh - 12625
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jfmpc.jfmpc_361_20

Rights and Permissions

Introduction: Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist), also known as incretin mimetics. This is the new approach for management of weight among diabetic patients along with glycemic controls. The study aims to explore the efficacy of Liraglutide on weight (body mass index) and glycemic control (HbA1C) among adult patients with type 2 diabetes mellitus in primary care center. Methods: Retrospective chart review of 149 adult patients with type II diabetic taking Liraglutide as a monotharepy for 6 months and more were included in the study. Analysis was done in SPSS version 22. Results: Total 149 chart reviews were done. The mean age of participants were 55.52 (SD: 8.167). Of total 58.4% were female and 70% were on insulin. Paired sample statistics reported that pre- and post-change in BMI and weight was significantly different with P value < 0.001. However pre- and post-change in the value of HBA1c was not significantly different with P value 0.561. Conclusion: Through this retrospective study we can conclude that Liraglutide has important effect on weight loss and reduction in BMI. However, further longitudinal studies with large sample size and multi-center randomized controlled trials are needed to generalize the effectiveness of Liraglutide among Saudi population.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed94    
    Printed2    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal